MA55046B1 - Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2 - Google Patents
Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2Info
- Publication number
- MA55046B1 MA55046B1 MA55046A MA55046A MA55046B1 MA 55046 B1 MA55046 B1 MA 55046B1 MA 55046 A MA55046 A MA 55046A MA 55046 A MA55046 A MA 55046A MA 55046 B1 MA55046 B1 MA 55046B1
- Authority
- MA
- Morocco
- Prior art keywords
- sup
- receptor modulators
- indole derivatives
- substituted indole
- img
- Prior art date
Links
- -1 N-SUBSTITUTED INDOLE Chemical class 0.000 title 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 title 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 title 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 150000003180 prostaglandins Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des dérivés de formule (I) <img file="imga0001.tif" frnum="0001" he="47" id="ia01" img-content="chem" img-format="tif" inline="no" orientation="portrait" pgnum="0001" wi="68"/> dans laquelle (R<sup>1</sup>)<sub>n</sub>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4a</sup>, R<sup>4b</sup>, R<sup>5a</sup>, R<sup>5b</sup> et Ar<sup>1</sup> sont tels que décrits dans la description, leur préparation, leurs sels pharmaceutiquement acceptables, et leur utilisation comme produits pharmaceutiques, des compositions pharmaceutiques contenant un ou plusieurs composés de formule (I), et notamment leur utilisation comme modulateurs des récepteurs de la prostaglandine 2 EP2 et/ou EP4.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2015077269 | 2015-11-20 | ||
| EP21186831.0A EP3928836B1 (fr) | 2015-11-20 | 2016-11-17 | Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA55046A MA55046A (fr) | 2021-12-29 |
| MA55046B1 true MA55046B1 (fr) | 2024-10-31 |
Family
ID=57326428
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA43251A MA43251B1 (fr) | 2015-11-20 | 2016-11-17 | Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2 |
| MA55046A MA55046B1 (fr) | 2015-11-20 | 2016-11-17 | Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA43251A MA43251B1 (fr) | 2015-11-20 | 2016-11-17 | Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2 |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US11241431B2 (fr) |
| EP (2) | EP3377483B9 (fr) |
| JP (2) | JP2018534328A (fr) |
| KR (1) | KR102352022B1 (fr) |
| CN (1) | CN108349949B (fr) |
| AU (1) | AU2016358242B2 (fr) |
| BR (1) | BR112018010291B1 (fr) |
| CA (1) | CA3002610C (fr) |
| CL (1) | CL2018001325A1 (fr) |
| CO (1) | CO2018005715A2 (fr) |
| CR (1) | CR20180323A (fr) |
| CY (1) | CY1124913T1 (fr) |
| DK (2) | DK3928836T3 (fr) |
| EA (1) | EA037953B1 (fr) |
| ES (2) | ES2994636T3 (fr) |
| FI (1) | FI3928836T3 (fr) |
| HR (2) | HRP20241521T1 (fr) |
| HU (2) | HUE056679T2 (fr) |
| IL (1) | IL259424B (fr) |
| LT (2) | LT3377483T (fr) |
| MA (2) | MA43251B1 (fr) |
| MX (1) | MX375978B (fr) |
| MY (1) | MY195888A (fr) |
| PE (1) | PE20181304A1 (fr) |
| PH (1) | PH12018501077B1 (fr) |
| PL (2) | PL3928836T3 (fr) |
| PT (2) | PT3928836T (fr) |
| RS (2) | RS62598B1 (fr) |
| SA (1) | SA518391588B1 (fr) |
| SG (1) | SG11201803627XA (fr) |
| SI (2) | SI3377483T1 (fr) |
| TW (2) | TWI719078B (fr) |
| UA (1) | UA123441C2 (fr) |
| WO (1) | WO2017085198A1 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20180323A (es) * | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| WO2018176134A1 (fr) | 2017-03-27 | 2018-10-04 | HYDRO-QUéBEC | Sels destinés à être utilisés dans des compositions d'électrolyte ou en tant qu'additifs d'électrode |
| MX388257B (es) | 2017-05-18 | 2025-03-19 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2. |
| JP7093791B2 (ja) | 2017-05-18 | 2022-06-30 | イドーシア ファーマシューティカルズ リミテッド | Ｐｇｅ２レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体 |
| AR111941A1 (es) | 2017-05-18 | 2019-09-04 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| EP3625223B1 (fr) | 2017-05-18 | 2021-08-11 | Idorsia Pharmaceuticals Ltd | Dérivés de pyrimidine |
| CN109678780A (zh) * | 2017-10-19 | 2019-04-26 | 中国石油化工股份有限公司 | 一种制备3-烷基吲哚衍生物的方法 |
| US11547712B2 (en) | 2017-11-20 | 2023-01-10 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| CN111819193A (zh) | 2018-01-05 | 2020-10-23 | 西奈山伊坎医学院 | 增加胰腺β细胞增殖的方法、治疗方法以及组合物 |
| AU2019240065A1 (en) | 2018-03-20 | 2020-09-24 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| CA3124353A1 (fr) * | 2018-12-31 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Composes inhibiteurs de kinase, compositions et methodes d'utilisation |
| EP3693359A1 (fr) * | 2019-02-08 | 2020-08-12 | Medibiofarma, S.L. | Nouveaux dérivés de n-benzyl-2-phénoxybenzamide en tant que modulateurs des récepteurs de la prostaglandine e2 (pge2) |
| WO2021060281A1 (fr) * | 2019-09-24 | 2021-04-01 | Ａｇｃ株式会社 | Antagoniste double des récepteurs ep2/ep4 de la prostaglandine e2 |
| EP4054719B1 (fr) | 2019-11-04 | 2026-02-11 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| CR20230165A (es) | 2020-09-15 | 2023-06-02 | Revolution Medicines Inc | Derivados indólicos como inhibidores de ras en el tratamiento del cáncer |
| EP4245301A4 (fr) | 2020-11-13 | 2024-08-21 | ONO Pharmaceutical Co., Ltd. | Traitement du cancer par utilisation combinée d'un antagoniste d'ep4 et d'un inhibiteur de point de contrôle immunitaire |
| WO2022272062A1 (fr) | 2021-06-24 | 2022-12-29 | Reservoir Neuroscience, Inc. | Composés antagonistes d'ep2 |
| WO2025229177A1 (fr) | 2024-05-02 | 2025-11-06 | Idorsia Pharmaceuticals Ltd | Formes cristallines d'un dérivé d'indole n-substitué |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5948786A (en) | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
| JP2003528144A (ja) | 2000-03-24 | 2003-09-24 | ファーマジーン ラボラトリーズ リミテッド | 頭痛治療のためのプロスタノイドｅｐ４受容体アンタゴニストの使用およびそのアンタゴニストについてのアッセイ |
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| GB0031302D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Napthalene derivatives |
| GB0031295D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Naphthalene derivatives |
| GB0103269D0 (en) | 2001-02-09 | 2001-03-28 | Glaxo Group Ltd | Napthalene derivatives |
| JP2005532291A (ja) | 2002-04-12 | 2005-10-27 | ファイザー株式会社 | 抗炎症薬および鎮痛薬としてのピラゾール化合物 |
| AU2003216579A1 (en) | 2002-04-12 | 2003-10-27 | Pfizer Inc. | Imidazole compounds as anti-inflammatory and analgesic agents |
| US20040023853A1 (en) | 2002-05-23 | 2004-02-05 | Peri Krishna G. | Antagonistic peptides of prostaglandin E2 receptor subtype EP4 |
| CN100408570C (zh) | 2003-01-29 | 2008-08-06 | 阿斯特兰德英国有限公司 | Ep4受体拮抗剂 |
| EP1661897B1 (fr) | 2003-08-26 | 2013-12-04 | Teijin Pharma Limited | Derive de pyrrolopyrimidinone |
| RS20060143A (sr) | 2003-09-03 | 2008-06-05 | Pfizer Inc., | Jedinjenja fenil ili piridil amida kao antagonisti prostaglandina e2 |
| EP1678147B1 (fr) | 2003-09-15 | 2012-08-08 | Lead Discovery Center GmbH | Derives d'aminopyrimidine a disubstitution 4,6 actifs sur le plan pharmaceutique en tant que modulateurs des proteine kinases |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| US7326732B2 (en) | 2004-02-12 | 2008-02-05 | Pharmagene Laboratories Limited | EP2 receptor agonists |
| JP4054368B2 (ja) | 2004-05-04 | 2008-02-27 | ファイザー株式会社 | 置換メチルアリール又はヘテロアリールアミド化合物 |
| CN1950334A (zh) | 2004-05-04 | 2007-04-18 | 辉瑞有限公司 | 邻位取代的芳基或杂芳基酰胺化合物 |
| HN2005000795A (es) * | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| ATE533766T1 (de) | 2005-05-19 | 2011-12-15 | Merck Canada Inc | Chinolinderivate als ep4-antagonisten |
| WO2006128129A2 (fr) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Traitement anticancereux |
| AR060403A1 (es) | 2006-04-12 | 2008-06-11 | Sanofi Aventis | Compuestos de amino- pirimidina 2,6- sustituidos -4- monosustituidos como antagonistas del receptor de prostaglandina d2 |
| CA2648729A1 (fr) | 2006-04-24 | 2007-11-01 | Merck Frosst Canada Ltd. | Derives d'indolamide comme antagonistes du recepteur ep4 |
| US7705035B2 (en) | 2006-06-12 | 2010-04-27 | Merck Frosst Canada Ltd. | Indoline amide derivatives as EP4 receptor ligands |
| US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| WO2008008059A1 (fr) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Agents anti-cancer et leurs utilisations |
| BRPI0714409A2 (pt) * | 2006-07-14 | 2013-03-12 | Novartis Ag | derivados de pirimidina como inibidores de alk-5 |
| CA2660133C (fr) | 2006-08-11 | 2015-10-27 | Merck Frosst Canada Ltd. | Derives de thiophenecarboxamide en tant que ligands du recepteur ep4 |
| WO2008039882A1 (fr) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | Combinaison de niacine et d'un antagoniste du récepteur de prostaglandine d2 |
| US8158671B2 (en) | 2007-02-26 | 2012-04-17 | Merck Canada Inc. | Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists |
| MX2009010297A (es) | 2007-03-26 | 2009-10-12 | Astellas Pharma Inc | Derivado de ornitina. |
| JP2010522218A (ja) | 2007-03-26 | 2010-07-01 | メルク フロスト カナダ リミテツド | Ｅｐ４受容体アンタゴニストとしてのナフタレン及びキノリンスルホニル尿素誘導体 |
| EP2014657A1 (fr) | 2007-06-21 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Diaminopyrimidine en tant que modulateurs du récepteur EP2 |
| US20110028463A1 (en) | 2007-07-03 | 2011-02-03 | Astellas Pharma Inc. | Amide compounds |
| CA2702008A1 (fr) | 2007-10-12 | 2009-04-16 | Ingenium Pharmaceuticals Gmbh | Inhibiteurs de proteine kinases |
| US8598202B2 (en) | 2008-02-19 | 2013-12-03 | Janssen Pharmaceutica Nv | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase |
| SI2565191T1 (sl) | 2008-05-14 | 2014-12-31 | Astellas Pharma Inc. | Derivati 4-(indol-7-ilkarbonilaminometil)cikloheksan karboksilne kisline kot EP4 receptorski antagonisti, uporabni za zdravljenje kronične ledvične odpovedi ali diabetične nefropatije |
| US20130225528A1 (en) | 2008-05-21 | 2013-08-29 | Ariad Pharmaceuticals, Inc. | Phosphorus Derivatives as Kinase Inhibitors |
| EP2320906B1 (fr) | 2008-08-14 | 2016-02-24 | Beta Pharma Canada Inc. | Dérivés d amides hétérocycliques en tant qu antagonistes du récepteur ep4 |
| CN102164942B (zh) | 2008-09-19 | 2017-02-15 | 生物科技研究有限公司 | 三萜系化合物及其使用的方法 |
| CN102224154A (zh) | 2008-09-25 | 2011-10-19 | 默克弗罗斯特加拿大有限公司 | 作为EP4受体拮抗剂的β-咔啉磺酰脲衍生物 |
| US8906914B2 (en) | 2009-08-18 | 2014-12-09 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid hydrolase |
| EP2504008A1 (fr) | 2009-11-23 | 2012-10-03 | Lexicon Pharmaceuticals, Inc. | Procédés et essais pour le traitement du syndrome du côlon irritable |
| CN103003264B (zh) | 2010-05-21 | 2014-08-06 | 切米利亚股份公司 | 嘧啶衍生物 |
| PH12013500467A1 (en) | 2010-09-21 | 2013-04-29 | Eisai R&D Man Co Ltd | Pharmaceutical composition |
| JP5273689B2 (ja) | 2010-09-29 | 2013-08-28 | 株式会社エヌビィー健康研究所 | ヒトプロスタグランジンｅ２受容体ｅｐ４に対する抗体 |
| WO2012066065A1 (fr) | 2010-11-17 | 2012-05-24 | Novartis Ag | Composés phényl-hétéroaryl amine et leurs utilisations |
| EA201390717A1 (ru) | 2010-11-17 | 2013-10-30 | Новартис Аг | 3-(аминоарил)пиридиновые соединения |
| CA2820109C (fr) | 2010-12-10 | 2018-01-09 | Rottapharm S.P.A. | Derives de pyridinamide en tant qu'antagonistes de recepteur ep4 |
| WO2012103071A2 (fr) | 2011-01-25 | 2012-08-02 | Eisai R&D Management Co., Ltd. | Composés et compositions |
| CA2830129C (fr) | 2011-03-24 | 2016-07-19 | Chemilia Ab | Nouveaux derives de pyrimidine |
| EP2702043A1 (fr) | 2011-04-29 | 2014-03-05 | Exelixis, Inc. | Inhibiteurs de la forme inductible de la 6-phosphofructose-2-kinase |
| US9518044B2 (en) | 2011-06-20 | 2016-12-13 | Emory University | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto |
| US9181279B2 (en) | 2011-07-04 | 2015-11-10 | Rottapharm Biotech S.R.L. | Cyclic amine derivatives as EP4 receptor antagonists |
| EP2554662A1 (fr) | 2011-08-05 | 2013-02-06 | M Maria Pia Cosma | Procédés pour le traitement de maladies rétiniennes dégénératives |
| WO2013090552A1 (fr) | 2011-12-13 | 2013-06-20 | Yale University | Compositions et procédés pour la réduction de l'épuisement de ctl |
| IN2014KN02601A (fr) | 2012-04-24 | 2015-05-08 | Vertex Pharma | |
| AR091429A1 (es) | 2012-06-29 | 2015-02-04 | Lilly Co Eli | Compuestos de fenoxietil piperidina |
| TWI572597B (zh) | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基－苯甲酸化合物 |
| EP2711364A1 (fr) * | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-(Indolyl ou benzimidazolyl)amino-2-(2-(indol-3-yl)éthyl)aminopyrimidines utiles pour le traitement du cancer |
| CA2888338C (fr) | 2012-11-27 | 2021-07-20 | Thomas Helledays Stiftelse For Medicinsk Forskning | Inhibiteurs mth1 pour le traitement du cancer |
| UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| EP2765128A1 (fr) | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Benzamides substitués présentant une activité vis-à-vis de récepteurs EP4 |
| TW201443004A (zh) | 2013-02-15 | 2014-11-16 | Lilly Co Eli | 苯氧基乙氧基化合物 |
| TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫－１ｈ－異喹啉化合物 |
| PT3009426T (pt) | 2013-06-12 | 2018-06-08 | Kaken Pharma Co Ltd | Derivado de 4-alquinilimidazole e medicamento compreendendo o mesmo como ingrediente ativo |
| EA029901B1 (ru) | 2013-09-04 | 2018-05-31 | Бристол-Майерс Сквибб Компани | Соединения для применения в качестве иммуномодуляторов |
| CU24362B1 (es) | 2013-09-06 | 2018-10-04 | Aurigene Discovery Tech Ltd | Derivados de 1,2,4-oxadiazol como inmunomoduladores |
| WO2015044900A1 (fr) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Composés immunomodulateurs thérapeutiques |
| ES2705342T3 (es) | 2013-10-17 | 2019-03-22 | Vertex Pharma | Co-cristales de (S)-N-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolin-4-carboxamida y derivados deuterados de la misma como inhibidores de DNA-PK |
| WO2015058031A1 (fr) | 2013-10-17 | 2015-04-23 | Vertex Pharmaceuticals Incorporated | Inhibiteurs d'adn-pk |
| EA028921B1 (ru) | 2013-12-17 | 2018-01-31 | Эли Лилли Энд Компани | Феноксиэтилы |
| DK3083554T3 (da) | 2013-12-17 | 2019-05-13 | Lilly Co Eli | Dimethylbenzoesyreforbindelser |
| TW201607943A (zh) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
| TW201623277A (zh) | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
| US10052332B2 (en) | 2014-04-29 | 2018-08-21 | Emory University | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto |
| US20170182003A1 (en) | 2014-05-23 | 2017-06-29 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of cancer |
| RU2016151390A (ru) | 2014-06-04 | 2018-07-17 | Томас Хелледайс Стифтелсе Фёр Медисинск Форскнинг | Ингибиторы мтн1 для лечения воспалительных и аутоиммунных заболеваний |
| WO2016021742A1 (fr) | 2014-08-07 | 2016-02-11 | Takeda Pharmaceutical Company Limited | Composés hétérocycliques utilisés en tant qu'antagonistes des récepteurs ccr4 |
| TWI739666B (zh) | 2015-01-09 | 2021-09-11 | 日商小野藥品工業股份有限公司 | 醫藥組成物 |
| EP3325490B1 (fr) | 2015-07-23 | 2019-12-18 | Takeda Pharmaceutical Company Limited | DÉRIVÉS DE 1,2,3,4-TÉTRAHYDRO-1,7-NAPHTYRIDIN-8-AMINE SUBSTITUÉS EN POSITION 1
ET LEUR UTILISATION EN TANT QU ANTAGONISTES DU RÉCEPTEUR EP4 |
| MX390051B (es) | 2015-10-16 | 2025-03-20 | Eisai R&D Man Co Ltd | Antagonistas de ep4. |
| CR20180323A (es) * | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| AU2017295720B2 (en) | 2016-07-13 | 2021-07-22 | Vertex Pharmaceuticals Incorporated | Methods, compositions and kits for increasing genome editing efficiency |
| EP3625223B1 (fr) | 2017-05-18 | 2021-08-11 | Idorsia Pharmaceuticals Ltd | Dérivés de pyrimidine |
| AR111941A1 (es) | 2017-05-18 | 2019-09-04 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| US20200069686A1 (en) | 2017-05-18 | 2020-03-05 | Idorsia Pharmaceuticals Ltd | N-substituted indole derivatives |
| JP7093791B2 (ja) | 2017-05-18 | 2022-06-30 | イドーシア ファーマシューティカルズ リミテッド | Ｐｇｅ２レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体 |
| MX388257B (es) | 2017-05-18 | 2025-03-19 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2. |
-
2015
- 2015-11-20 CR CR20180323A patent/CR20180323A/es unknown
-
2016
- 2016-11-17 MX MX2018005268A patent/MX375978B/es active IP Right Grant
- 2016-11-17 LT LTEPPCT/EP2016/078028T patent/LT3377483T/lt unknown
- 2016-11-17 WO PCT/EP2016/078028 patent/WO2017085198A1/fr not_active Ceased
- 2016-11-17 AU AU2016358242A patent/AU2016358242B2/en active Active
- 2016-11-17 MA MA43251A patent/MA43251B1/fr unknown
- 2016-11-17 MA MA55046A patent/MA55046B1/fr unknown
- 2016-11-17 PL PL21186831.0T patent/PL3928836T3/pl unknown
- 2016-11-17 FI FIEP21186831.0T patent/FI3928836T3/fi active
- 2016-11-17 HR HRP20241521TT patent/HRP20241521T1/hr unknown
- 2016-11-17 CN CN201680066933.8A patent/CN108349949B/zh active Active
- 2016-11-17 PT PT211868310T patent/PT3928836T/pt unknown
- 2016-11-17 EA EA201891179A patent/EA037953B1/ru unknown
- 2016-11-17 BR BR112018010291-1A patent/BR112018010291B1/pt active IP Right Grant
- 2016-11-17 SI SI201631400T patent/SI3377483T1/sl unknown
- 2016-11-17 ES ES21186831T patent/ES2994636T3/es active Active
- 2016-11-17 MY MYPI2018701873A patent/MY195888A/en unknown
- 2016-11-17 DK DK21186831.0T patent/DK3928836T3/da active
- 2016-11-17 JP JP2018526184A patent/JP2018534328A/ja not_active Ceased
- 2016-11-17 PE PE2018000994A patent/PE20181304A1/es unknown
- 2016-11-17 RS RS20211424A patent/RS62598B1/sr unknown
- 2016-11-17 DK DK16797577.0T patent/DK3377483T3/da active
- 2016-11-17 UA UAA201806812A patent/UA123441C2/uk unknown
- 2016-11-17 CA CA3002610A patent/CA3002610C/fr active Active
- 2016-11-17 LT LTEP21186831.0T patent/LT3928836T/lt unknown
- 2016-11-17 SI SI201631863T patent/SI3928836T1/sl unknown
- 2016-11-17 HU HUE16797577A patent/HUE056679T2/hu unknown
- 2016-11-17 HU HUE21186831A patent/HUE069520T2/hu unknown
- 2016-11-17 PT PT167975770T patent/PT3377483T/pt unknown
- 2016-11-17 US US15/777,597 patent/US11241431B2/en active Active
- 2016-11-17 ES ES16797577T patent/ES2897954T3/es active Active
- 2016-11-17 PL PL16797577T patent/PL3377483T3/pl unknown
- 2016-11-17 EP EP16797577.0A patent/EP3377483B9/fr active Active
- 2016-11-17 KR KR1020187017474A patent/KR102352022B1/ko active Active
- 2016-11-17 EP EP21186831.0A patent/EP3928836B1/fr active Active
- 2016-11-17 RS RS20241254A patent/RS66179B1/sr unknown
- 2016-11-17 SG SG11201803627XA patent/SG11201803627XA/en unknown
- 2016-11-17 HR HRP20211678TT patent/HRP20211678T1/hr unknown
- 2016-11-18 TW TW105137938A patent/TWI719078B/zh active
- 2016-11-18 TW TW109133855A patent/TWI754397B/zh active
-
2018
- 2018-05-15 SA SA518391588A patent/SA518391588B1/ar unknown
- 2018-05-16 IL IL259424A patent/IL259424B/en active IP Right Grant
- 2018-05-17 CL CL2018001325A patent/CL2018001325A1/es unknown
- 2018-05-18 PH PH12018501077A patent/PH12018501077B1/en unknown
- 2018-05-30 CO CONC2018/0005715A patent/CO2018005715A2/es unknown
-
2021
- 2021-04-13 JP JP2021067831A patent/JP7228618B2/ja active Active
- 2021-11-30 CY CY20211101035T patent/CY1124913T1/el unknown
- 2021-12-13 US US17/549,828 patent/US12011444B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55046B1 (fr) | Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2 | |
| MA54653B1 (fr) | Modulateurs du récepteur de cxcr7 pipéridine | |
| MA49127B1 (fr) | Dérivés d'indole n-substitués | |
| MA56883B1 (fr) | Dérivés de 2-hydroxycycloalcane-1-carbamoyle | |
| MA42678B1 (fr) | Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5 | |
| MA37400B1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
| MA45223A (fr) | Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant | |
| MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA53399B1 (fr) | Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine | |
| MA38138A1 (fr) | Dérivés inédits de quinolone | |
| TN2009000450A1 (fr) | Derives de pyridine | |
| MA43979B1 (fr) | Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques | |
| MA34474B1 (fr) | Agonistes de gpr40 | |
| MA42410A (fr) | Oxystérols et leurs méthodes d'utilisation | |
| MA49126B1 (fr) | Dérivés de phényle utilisés en tant que modulateurs des récepteurs des pge2 | |
| MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
| TN2016000188A1 (fr) | Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs. | |
| MA38999A1 (fr) | Nouveaux composés hétérocycliques | |
| MA38854B1 (fr) | Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique | |
| MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
| MA39165A1 (fr) | Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires | |
| MA38679A1 (fr) | Modulateurs du récepteur de cxcr7 | |
| MA33760B1 (fr) | Dérivés spirolactames et leurs utilisations | |
| MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
| MA44965A (fr) | Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3 |